Karyopharm Therapeutics price to sales ratio KPTI
Market value divided by revenue over the last twelve months, since 2019.
- Today, Nov 2, 2026
- 0.0×
- 7-year median
- 1.6×
- Against its 7-year history
- 0th
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 0.0× to 76.9×
- Peer median
- 1.3×
Karyopharm Therapeutics' price to sales ratio is 0.0× as of Nov 2, 2026.
That is below its 7-year median of 1.6×, lower than on 100% of days in the last 7 years.
Over that time it ranged from 0.0× in Nov 2026 to 76.9× in Nov 2019.
The median for 10 healthcare stocks of a similar size is 1.3×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.0× | 0.0× | 1.6× |
| 2025 | 0.5× | 0.2× | 0.7× |
| 2024 | 0.6× | 0.5× | 1.2× |
| 2023 | 0.7× | 0.6× | 3.1× |
| 2022 | 1.1× | 0.8× | 9.1× |
| 2021 | 4.1× | 3.4× | 14.2× |
| 2020 | 12.5× | 11.4× | 50.1× |
| 2019 | 52.5× | 13.8× | 76.9× |
Against its peers
Companies in Healthcare nearest Karyopharm Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| KPTIKaryopharm Therapeutics | 0.0× |
| OXBROXBRIDGE RE HOLDINGS | 2.4× |
| EDUCEducational Development | 0.4× |
| GTIMGood Times Restaurants | 0.1× |
| MDRRMedalist Diversified | 1.9× |
| VIPVulcan Infrastructure & Power | 0.4× |
| BCGBinah Capital | 0.1× |
| MXCMexco Energy | 2.8× |
| ATCHAtlasClear | 1.0× |
| CKXCKX Lands | 31.5× |
| MSGMMotorsport Games | 1.6× |
| Peer median | 1.3× |
Where Karyopharm Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Karyopharm Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.